Lilly joins ICAgen-Sphinx ion channel screening agreement
Ion channel biotech company ICAgen has expanded its April 1993 drug discovery agreement with Sphinx Pharmaceuticals to bring Sphinx's new owner Eli Lilly into the deal.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com